论文部分内容阅读
以鼠甲状腺细胞株（ＦＲＴＬ－５）为靶细胞，３Ｈ－ＴｄＲ掺入为生长指标和ｃＡＭＰ产生量为功能指标，对８６例自身免疫性甲状腺病（ＡＩＴＤ）甲状腺生长刺激抗体（ＴＧＡｂ）及部分患者甲状腺功能刺激抗体（ＴｓＡｂ）活性进行了测定。甲状腺Ⅱ°和Ⅲ°肿大的活动性Ｇｒａｖｅｓ病（ＧＤ）的ＴＧＡｂ阳性率为６４％，而Ⅰ°者为２１％。ＧＤ的ＴＧＡｂ与ＴｓＡｂ括性及Ｔ３值不相关。散发性甲状腺肿大患者ＴＧＡｂ阳性率为３１％（５／１６）。提示ＧＤ申状腺肿大与患者体内存在的能使甲状腺细胞增生的ＴＧＡｂ有关。散发性甲状腺肿大患者体内存在自身免疫性紊乱。
To investigate the role of thyroid stimulating antibody (TGAb) in thyroid cell line (TITB) and its role in the growth of thyroid cells (FRIT-5) as target cells and 3H-TdR incorporation as growth index and cAMP production, The thyroid function stimulating antibody (TsAb) activity was measured in patients. The positive rate of TGAb was 64% in active Graves’ disease (GD) with thyroid enlargement Ⅱ ° and Ⅲ °, and 21% in Ⅰ °. GD TGAb and TsAb inclusive and T3 values are not related. The positive rate of TGAb in patients with sporadic thyroid enlargement was 31% (5/16). Tip GD in the enlargement of the thyroid gland and thyroid cell proliferation in patients with existing TGAb related. Sporadic goiter in patients with autoimmune disorders.